tradmap

SUPN Supernus Pharmaceuticals, Inc.

$44.38 +1.96%

Healthcare · Pharmaceutical Preparations

Supernus Pharmaceuticals, Inc. (SUPN) is a healthcare company in the Pharmaceutical Preparations industry, with a market capitalization of $2.6 billion. Shares last traded at $44.38, 25.3% below their 52-week high. Over the past year the stock is up 37.4%. Net profit margin is -5.4%, below the peer median of -0.1%. Revenue grew 8.6% year over year.

Market Cap
$2.6B
Shares Out
58.0M
EPS (TTM)
$-0.67
P/E Ratio
P/S Ratio
3.58
P/B Ratio
2.39
Dividend / Share
Dividend Yield
52-Week High
$59.45
52-Week Low
$30.84
Volume
47,218
Avg Vol (3m)
34,518.159

Performance

1W
-2.54%
1M
-6.85%
3M
-9.11%
6M
-8.11%
YTD
-10.27%
1Y
+37.35%

Daily candles · volume · SMA(20)/SMA(50) · Databento EQUS.MINI.

Technicals

RSI (14)
40.47
SMA (50)
$48.06
SMA (200)
$48.99
Price vs SMA50
-7.65%
Price vs SMA200
-9.40%
ATR (14)
$1.90

Financials

Revenue
$719M
Net Income
$-39M
Gross Margin
Operating Margin
-8.7%
Net Margin
-5.4%
Return on Equity
-3.6%
Return on Assets
-2.6%
Current Ratio
1.96
Debt / Equity
0.00
Revenue Growth (YoY)
+8.6%

Latest reported annual period ending 2025-12-31 · SEC EDGAR/XBRL.

Recent earnings

PeriodEPS (diluted)Reported
Q1 2026 $-0.04 2026-05-05
FY 2025 $-0.68 2026-03-02
Q3 2025 $-0.61 2025-11-06
Q2 2025 $0.19 2025-08-05
Q1 2026 $-0.21 2026-05-05
FY 2025 $1.32 2026-03-02

Full earnings history →

Pharmaceutical Preparations peers

SUPN vs 14 industry peers (Pharmaceutical Preparations), by market cap.

P/S vs peers
3.58 / 3.54 med
+1% premium
Net margin vs peers
-5.4% / -0.1% med
below median
1–14 of 14
LLYLilly (Eli)$1.04T50.1615.8831.7%-1.17%
JNJJohnson & Johnson$549.8B20.515.8428.5%-2.42%
ONCBeone Medicines Ltd.$390.6B1361.2673.105.4%+2.83%
ABBVAbbVie$382.5B90.516.256.9%-2.16%
MRKMerck$281.6B15.434.3328.1%-1.30%
ABTAbbott Laboratories$154.3B23.653.4814.7%+0.09%
PFEPfizer$143.7B18.502.3012.4%-2.89%
VRTXVertex Pharmaceuticals$114.6B28.999.5532.9%-1.63%
BMYBristol Myers Squibb$110.3B15.632.2914.6%-2.35%
REGNRegeneron Pharmaceuticals$63.4B14.084.4231.4%+0.38%
ALNYAlnylam Pharmaceuticals$36.9B117.579.938.4%-1.66%
TEVATeva Pharmaceutical Industries Ltd$36.6B25.982.128.2%-3.33%
ZTSZoetis$33.1B12.373.4928.2%+2.09%
RPRXRoyalty Pharma Plc$23.1B30.029.7332.4%-1.30%

Source: SEC EDGAR (fundamentals/EPS/dividends) · Databento EQUS.MINI (prices) · market cap & yield computed by tradmap. Informational only — not financial advice.